RJA
TARO

Raymond James & Associates’s Taro Pharmaceutical Industries Ltd. TARO Stock Holding History

Raymond James & Associates’s Portfolio TARO Stock Details TARO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-2,010
Closed -$222K – 3376
2016
Q3 		$222K Buy
2,010
+102
+5% +$13.5K ﹤0.01% 2805
2016
Q2 		$278K Sell
1,908
-3,907
-67% -$554K ﹤0.01% 2458
2016
Q1 		$833K Buy
+5,815
New +$826K ﹤0.01% 1757

Other funds holding TARO

Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
MICM
Matthews International Capital Management San Francisco, California $246M AUM 10.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
APG Asset Management
APG Asset Management Amsterdam, Netherlands $31.6B AUM 19.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James & Associates's TARO Position: Q4 2016 in Review

Raymond James & Associates sold out of Taro Pharmaceutical Industries Ltd. (TARO) in Q4 2016, closing a stake of 2,010 shares — an estimated $222K sold.

Raymond James & Associates first reported a position in TARO in Q1 2016 and held it in 3 quarters. The position peaked at $833K in Q1 2016. 151 funds tracked by Wall St. Rank hold TARO as of Q4 2016.

  • Raymond James & Associates reported no remaining Taro Pharmaceutical Industries Ltd. position as of Q4 2016 after selling out during the quarter.
  • Raymond James & Associates sold 2,010 Taro Pharmaceutical Industries Ltd. shares in Q4 2016, an estimated $222K.
  • Raymond James & Associates first reported a position in Taro Pharmaceutical Industries Ltd. in Q1 2016 and held it in 3 quarters.
  • Raymond James & Associates's Taro Pharmaceutical Industries Ltd. position peaked at $833K in Q1 2016.
  • 151 funds tracked by Wall St. Rank held Taro Pharmaceutical Industries Ltd. as of Q4 2016.

Based on Raymond James & Associates's 13F filing for Q4 2016, filed 14 Feb 2017.